Estimaciones de analistas de Wall Street para Adagene Inc. (ADAG): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 5 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2027-03-31 | $-0.21 | ||
| 2026-08-12 | $-0.23 | $-0.23 | +0.0% |
| 2026-04-01 | $-0.07 | $-0.28 | +75.0% |
| 2026-03-23 | $-0.11 | $-0.19 | +42.4% |
| 2025-08-12 | $-0.23 | $-0.32 | +28.1% |
| 2025-03-24 | $-0.29 | $-0.33 | +12.1% |
| 2024-07-25 | $-0.31 | $-0.41 | +24.4% |
| 2024-04-02 | $-0.24 | $-0.42 | +43.5% |
Ratios de valoración
| Precio / Valor contable | 1.40 |
| EV / EBITDA | -0.59 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | $1.5M | $480000 | $480000 | $10.2M | $9.3M | $18.1M | $103204 | $7.7M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $1.5M | $480000 | $480000 | $10.2M | $9.3M | $18.1M | -$823044 | $7.7M |
| I+D | $16.1M | $16.2M | $16.2M | $68.1M | $81.3M | $36.6M | $28.8M | $22.0M |
| Generales y Administrativos | $2.8M | $3.4M | $3.4M | $14.4M | $11.9M | $8.7M | $7.3M | $7.1M |
| Gastos Operativos | $18.8M | $19.6M | $19.6M | $82.5M | $93.2M | $41.8M | $36.1M | $29.1M |
| Beneficio Operativo | -$17.3M | -$19.2M | -$19.2M | -$72.4M | -$83.9M | -$23.7M | -$36.0M | -$21.4M |
| EBITDA | -$14.3M | -$15.5M | -$41.3M | -$70.0M | -$77.4M | -$15.0M | -$31.7M | -$16.9M |
| Gastos por Intereses | $91085 | $138096 | $202165 | $363762 | $693323 | $1.1M | $851874 | $463132 |
| Beneficio Antes de Impuestos | -$15.3M | -$16.4M | -$16.4M | -$71.5M | -$79.5M | -$17.3M | -$33.4M | -$17.9M |
| Impuestos | -$547003 | 0 | $3164 | $1.7M | $459055 | $1.7M | -$17553 | -$297860 |
| Beneficio Neto | -$14.7M | -$17.3M | -$16.4M | -$73.2M | -$80.0M | -$18.9M | -$33.4M | -$17.6M |
| BPA | $-1.51 | $-0.49 | $-0.59 | $-2.29 | $-2.31 | $-0.55 | $-0.95 | $-0.46 |
| BPA Diluido | $-1.51 | $-0.49 | $-0.59 | $-2.29 | $-2.31 | $-0.54 | $-0.95 | $-0.46 |
| Acciones en Circulación (Diluidas) | $9.7M | $35.3M | $28.1M | $32.0M | $34.6M | $35.0M | $36.0M | $37.8M |
Precio
| Precio | $3.37 |
| Capitalización | $127M |
| Bolsa | NASDAQ |
| País | CN |
Empresas relacionadas: ACET · CRVO · FBIO · GANX · LITS · NRXP · NTRB
Explorar sector: Healthcare · Biotechnology
Más secciones de ADAG: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones